July 18, 2014
2 min read
Save

MenACWY-CRM booster dose elicited robust immune response

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Recent data show children who received a booster dose of MenACWY-CRM following primary immunization with either MenACWY-CRM-D or MenACWY-D had strong immune responses 2 years after vaccination.

Roger Baxter, MD, of Kaiser Permanente Vaccine Study Center in Oakland, Calif., and colleagues assigned children aged 19.2±2.3 years to groups according to whether they had previously received primary vaccination with MenACWY-CRM (Menveo, Novartis) (n=131) or MenACWY-CRM-D (Menactra, Sanofi Pasteur) (n=76); a booster dose of MenACWY-CRM 3 years after primary vaccination with MenACWY-CRM (n=44) or MenACWY-D (n=31); or no vaccination (n=107). Human complement serum bactericidal activity (hSBA) was assessed for serogroups A, C, W and Y. The study was conducted from February 2009 to November 2012.

Roger Baxter, MD

Roger Baxter

 

Five years after primary vaccination, children who received MenACWY-CRM or MenACWY-D maintained hSBA 1:8 or greater against serogroups C, W and Y. There was a greater percentage of children who received MenACWY-CRM with hSBA 1:8 or less for all four serogroups compared with unvaccinated children. Percentages of children who received MenACWY-D were higher for serogroups A and C.

Researchers found similar results when assessing hSBA geometric mean titers (GMTs) 5 years after primary vaccination. Among both vaccine groups, the highest GMTs were against serogroup W. Children who received MenACWY-CRM had uniformly higher GMTs than unvaccinated children for all four serogroups. There were no significant differences in percentages of children with hSBA 1:8 or greater or GMTs between those who received MenACWY-CRM or MenACWY-D.

Regarding persistence after booster vaccination, both groups had strong responses to a booster dose of MenACWY-CRM one month after booster; and this response persisted for serogroups C, W, and Y through 2 years after booster vaccination.

There were greater percentages of children with hSBA 1:8 or greater at 2 years after the booster vaccination compared with 21 months after primary vaccination. Both vaccine groups had greater numbers of children with hSBA 1:8 or greater compared with unvaccinated children. Researchers found similar results for GMTs at 21 months after primary vaccination and 2 years after booster vaccination.

“Overall, these findings support the use of MenACWY-CRM for the routine boosting of adolescents after primary vaccination with either MenACWY-CRM or MenACWY-D, in accordance with the recent recommendation by the US [Advisory Committee on Immunization Practices],” the researchers concluded.

Disclosure: The study was funded by Novartis Vaccines.